We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Multiplex Cytokine Assays Need Independent Quality Controls

By Biotechdaily staff writers
Posted on 12 Sep 2007
Quality control is particularly important for multiplex cytokine assays due to the greater demands of performing several assays in a single procedure.

Cytokines are signaling proteins, released primarily by immune cells and are implicated in a number of diseases. More...
The complexity of the cytokine signaling network and the roles played by different cytokines is critical to understanding both normal and pathologic processes. There has been an emergence of multiplex assays that give a picture of multiple cytokines in a single sample.

Many cytokine assays suffer from inconsistent accuracy and poor precision. In addition, different manufacturers' assays produce markedly different results depending on the production process and the assay method. Using kit controls can add to the problem. Kit controls are often manufactured using the same materials and production methods as the kit components, then optimized for a specific instrument. They can actually conceal problems arising from the reagents, calibrators, or instruments.

Independent quality controls allow laboratories to validate calibrations, monitor accuracy and precision, and reduce interlaboratory variation. Randox Laboratories (Crumlin, UK) offers tri-level cytokine controls for cytokine assays and high-sensitivity cytokine assays. These controls are suitable for multiplex assays and for multi-center clinical trials.

The Randox controls are 100% human and do not contain preservatives. They are lyophilized and have a two-year shelf life. When reconstituted, they are stable for four hours at +2-8°C or seven days at –20°C. The 12 analytes include seven interleukins (IL-1a, IL-1ß, IL-2, IL-4, IL-6, IL-8, IL-10), epidermal growth factor (EGF), interferon-gamma (IFN-γ), monocyte chemotactic protein-1 (MCP-1), vascular endothelial growth factor (VEGF), and tumor necrosis factor-alpha (TNFa).


Related Links:
Randox Laboratories

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Hematology Consumables
Bioblood Devices
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The findings point to the feasibility of a quick, noninvasive urine-based approach to support earlier decision-making in multiple psychiatric conditions (photo credit: Shutterstock)

Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders

Delays in diagnosing serious psychiatric conditions can leave patients without timely support and complicate treatment planning. For bipolar disorder, average time to diagnosis can exceed nine years, and... Read more

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.